Sugi Predict

Sugi Predict / Compounds / SCHEMBL334824

SCHEMBL334824

SCHEMBL334824

O=C1N[N]c2ccccc21

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ GSK3B P49841 1/20 0.44
▸ KDM4E B2RXH2 5/20 0.42
▸ LMNA P02545 5/20 0.42
▸ TDP1 Q9NUW8 3/20 0.42
▸ CASP3 P42574 2/20 0.38
▸ CASP7 P55210 2/20 0.38
▸ CASP6 P55212 2/20 0.38
▸ CASP8 Q14790 2/20 0.38
▸ CASP2 P42575 1/20 0.38
▸ KMT2A Q03164 3/20 0.38
▸ CDC25B P30305 3/20 0.38
▸ MEN1 O00255 2/20 0.38
▸ MAPT P10636 3/20 0.37
▸ GAA P10253 1/20 0.37
▸ MAOA P21397 3/20 0.37
▸ MAOB P27338 2/20 0.37
▸ PDGFRA P16234 1/20 0.37
▸ FER P16591 1/20 0.37
▸ LTK P29376 1/20 0.37
▸ CDK8 P49336 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20504712 1.00 GSK3B (0.44) GSK3BKDM4ELMNATDP1CASP3
SCHEMBL8425345 0.86 CASP3 (0.45) GSK3BKDM4ELMNATDP1CASP3
SCHEMBL5142142 0.77 GSK3B (0.41) GSK3BKDM4ELMNATDP1CASP3
SCHEMBL131636 0.76 GSK3B (0.50) GSK3BKDM4ELMNATDP1CASP3
SCHEMBL209273 0.74 KDM4E (0.46) GSK3BKDM4ELMNATDP1CASP3
SCHEMBL555451 0.68 GSK3B (0.52) GSK3BKDM4ELMNATDP1CASP3
SCHEMBL21296775 0.68 GSK3B (0.52) GSK3BKDM4ELMNATDP1CASP3
SCHEMBL11011352 0.67 CA12 (0.45) GSK3BLMNACASP3CASP7CASP6
SCHEMBL24971620 0.63 KDM4E (0.44) GSK3BKDM4ELMNATDP1CASP3
Phthalimide SCHEMBL64 0.62 GSK3B (1.00) GSK3BKDM4ELMNATDP1CASP3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 90 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12011444-B2 N-substituted indole derivatives as PGE2 receptor modulators IDORSIA PHARMACEUTICALS LTD (CH) 2024-06-18 — — US claimed
US-20220175775-A1 N-SUBSTITUTED INDOLE DERIVATIVES AS PGE2 RECEPTOR MODULATORS IDORSIA PHARMACEUTICALS LTD (CH) 2022-06-09 — — US claimed
EP-3928836-A1 N-SUBSTITUTED INDOLE DERIVATIVES AS PGE2 RECEPTOR MODULATORS Idorsia Pharmaceuticals Ltd (CH) 2021-12-29 — — EP claimed
CN-108349949-B N-substituted indole derivatives as PGE2 receptor modulators 爱杜西亚药品有限公司 2020-11-17 — — CN claimed
US-20200289507-A1 N-SUBSTITUTED INDOLE DERIVATIVES AS PGE2 RECEPTOR MODULATORS IDORSIA PHARMACEUTICALS LTD (CH) 2020-09-17 — — US claimed
EP-3070081-B1 BENZOTHIAZOL-6-YL ACETIC ACID DERIVATIVES AND THEIR USE FOR TREATING AN HIV INFECTION GILEAD SCIENCES INC (US) 2018-02-28 — — EP claimed
US-20160015690-A1 THERAPEUTIC COMPOUNDS GILEAD SCIENCES, INC. 2016-01-21 — — US claimed
US-8987250-B2 Therapeutic compounds GILEAD SCIENCES, INC. (US) 2015-03-24 — — US claimed
US-5955464-A USE OF THE RECEPTOR TYROSINE KINASE INHIBITORY PROPERTIES OF THE COMPOUNDS IN THE TREATMENT OF PROLIFERATIVE DISEASE SUCH AS CANCER ZENECA LIMITED (GB) 1999-09-21 — — US claimed
EP-0794953-B1 QUINAZOLINE DERIVATIVES ZENECA LTD (GB) 1999-05-06 — — EP claimed
US-12011444-B2 N-substituted indole derivatives as PGE2 receptor modulators IDORSIA PHARMACEUTICALS LTD (CH) 2024-06-18 — — US disclosed
US-11839613-B2 Pyrimidine derivatives as PGE2 receptor modulators IDORSIA PHARMACEUTICALS LTD (CH) 2023-12-12 — — US disclosed
WO-2023211990-A1 BICYCLIC HETEROCYCLIC AMIDE INHIBITORS OF NA V1.8 FOR THE TREATMENT OF PAIN SITEONE THERAPEUTICS, INC. (US) 2023-11-02 — — WO disclosed
US-11712438-B2 Phenyl derivatives as PGE2 receptor modulators IDORSIA PHARMACEUTICALS LTD (CH) 2023-08-01 — — US disclosed
US-20220175775-A1 N-SUBSTITUTED INDOLE DERIVATIVES AS PGE2 RECEPTOR MODULATORS IDORSIA PHARMACEUTICALS LTD (CH) 2022-06-09 — — US disclosed
WO-1994004528-A1 ETHER-CONTAINING INHIBITORS OF 5-LIPOXYGENASE ABBOTT LABORATORIES (US) 1994-03-03 — — WO disclosed
US-5278177-A Enzyme inhibitory IMPERIAL CHEMICAL INDUSTRIES PLC (GB) 1994-01-11 — — US disclosed
US-5268379-A Quinolin-1-one structure ABBOTT LABORATORIES (US) 1993-12-07 — — US disclosed
US-5179115-A Antiinflammatory agents, antiallergens IMPERIAL CHEMICAL INDUSTRIES PLC (GB) 1993-01-12 — — US disclosed
EP-0462831-A2 Bicyclic pyran derivatives and their use as inhibitors of 5-lipoxygenase ZENECA LIMITED (GB) 1991-12-27 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11712438-B2 Phenyl derivatives as PGE2 receptor modulators PTGER1, PTGER4, PTGER2 GSK3B 3216/4885KDM4E 842/4885LMNA 4359/4885
US-20200289507-A1 N-SUBSTITUTED INDOLE DERIVATIVES AS PGE2 RECEPTOR MODULATORS PTGER1, PTGER4, PTGER2 GSK3B 1839/4885KDM4E 2755/4885LMNA 3249/4885
US-20220175775-A1 N-SUBSTITUTED INDOLE DERIVATIVES AS PGE2 RECEPTOR MODULATORS PTGER1, PTGER4, PTGER2 GSK3B 1839/4885KDM4E 2755/4885LMNA 3249/4885
US-11839613-B2 Pyrimidine derivatives as PGE2 receptor modulators PTGER1, PTGER4, PTGER2 GSK3B 3814/4885KDM4E 1571/4885LMNA 4601/4885
US-12011444-B2 N-substituted indole derivatives as PGE2 receptor modulators PTGER1, PTGER4, PTGER2 GSK3B 1839/4885KDM4E 2755/4885LMNA 3249/4885
US-20160015690-A1 THERAPEUTIC COMPOUNDS NQO1, HAVCR2, CCR5 GSK3B 1719/4885KDM4E 4221/4885LMNA 3781/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.